A New Scientific Review Supports Lacidofil as a Probiotic Adjuvant for Helicobacter Pylori Eradication

Montreal, Canada, January 13, 2026 – A newly published comprehensive review in Microorganisms highlights the efficacy and mechanisms of action of one of Lallemand Health Solutions’ key formulas, Lacidofil®, a probiotic blend of Lacticaseibacillus rhamnosus Rosell®-11 and Lactobacillus helveticus Rosell®-52, as an adjuvant to standard Helicobacter pylori eradication therapy.

The review, titled “Probiotics as Adjuvants to Standard Helicobacter pylori Treatment: Evidence for the Use of Lacidofil®, an established blend of thoroughly characterized strains”, synthesizes findings from eight clinical trials, three in children and five in adults, and multiple preclinical studies. Results show eradication rates are consistently improved in participants receiving standard therapy supplemented with Lacidofil®. In studies conducted in adults, the eradication rate reached 90% in the Lacidofil® group, while none of the standard treatment alone or with a placebo did. Furthermore, Lacidofil® significantly helped with the management of side effects such as antibiotic-associated diarrhea, nausea, and taste disturbances.

“Lacidofil® has been studied for over two decades and is backed by robust clinical and mechanistic data,” says Sylvie Binda, Vice President of Research and Development at Lallemand Health Solutions. “This review confirms its role in enhancing treatment outcomes and supporting or restoring gut microbiota balance during and after H. pylori therapy.”

The review also presents mechanistic insights from in vitro and in vivo studies, demonstrating the Lacidofil® formula’s, and its individual strains’, ability to:

These findings were recognized by Health Canada, who approved the following claim, in addition to “normalizing and restoring intestinal flora”:

Helps to reduce the incidence of antibiotic associated diarrhea in those who are undergoing antibiotic therapy for Helicobacter pylori gastrointestinal infections.

About H. pylori
Excerpt from the article published in Microorganisms:

Helicobacter pylori (H. pylori) is a bacterial pathogen that infects about half of the world population [1]. While most carriers remain asymptomatic, and therefore untreated, long-term H. pylori infection is associated with several conditions [1,2,3]. Therapies for H. pylori eradication were initially effective, but eradication rates have declined steadily over the last 20 to 30 years. Therefore, the use of adjuvants, such as probiotic supplements, has been suggested to improve efficacy [4,5].

About Lallemand Health Solutions – Leading Probiotics Forward

Lallemand Health Solutions is a vertically integrated global leader in the development and manufacturing of probiotic yeast and bacteria-based formulas. With over 600 probiotic formulas marketed in more than 70 countries, the company’s solutions support gut health, immune function, mental well-being, and more. Lallemand’s commitment to scientific excellence is reflected in its ambitious research program and adherence to Good Manufacturing Practices.

Press Contact

Marilou Luneau
Communications Manager
Lallemand Health Solutions
[email protected]

References